TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the launch of the EMBARK Psychedelic Facilitator Training Program. Led by a team of esteemed faculty, the program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful…
